EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. - Wikidata - awgldk - TriplyDB

EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.

EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.

http://www.wikidata.org/entity/Q34803805

about

Targeting EZH2 in cancer Noncoding RNA control of cellular senescence Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes EZH2 as a mediator of treatment resistance in melanoma Diverse involvement of EZH2 in cancer epigenetics Epigenetic regulation in human melanoma: past and future A new lncRNA, APTR, associates with and represses the CDKN1A/p21 promoter by recruiting polycomb proteins.Age-associated chromatin relaxation is enhanced in Huntington's disease mice.Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS EZH2: not EZHY (easy) to deal.Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway.Long non-coding RNA LUCAT1 is associated with poor prognosis in human non-small lung cancer and regulates cell proliferation via epigenetically repressing p21 and p57 expression NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.EZH2 is associated with malignant behavior in pancreatic IPMN via p27Kip1 downregulation.Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma.ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 gene.The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.Identification of microRNA-mRNA functional interactions in UVB-induced senescence of human diploid fibroblasts Ezh2 mediated H3K27me3 activity facilitates somatic transition during human pluripotent reprogramming Targeting histone methyltransferase EZH2 as cancer treatment.MK3 modulation affects BMI1-dependent and independent cell cycle check-points.Epigenetic biomarkers in skin cancer.Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.Increased expression of long noncoding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57.PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer.Molecular mechanisms of flavonoids in melanin synthesis and the potential for the prevention and treatment of melanoma HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.Role of EZH2 histone methyltrasferase in melanoma progression and metastasis Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma E2F1-induced upregulation of long noncoding RNA LINC00668 predicts a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically silencing of CKIs EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells.Long noncoding RNA BLACAT1 indicates a poor prognosis of colorectal cancer and affects cell proliferation by epigenetically silencing of p15 The role of histone methyltransferase EZH2 in myelodysplastic syndromes.Epigenetic cancer prevention mechanisms in skin cancer.Roles of enhancer of zeste homolog 2: from skeletal muscle differentiation to rhabdomyosarcoma carcinogenesis.Genetic alterations and personalized medicine in melanoma: progress and future prospects.EZH2: an emerging role in melanoma biology and strategies for targeted therapy.Polycomb group proteins--epigenetic repressors with emerging roles in melanocytes and melanoma.

P2860

Q26769027-9F2D69AA-414C-4C22-A433-97B2669972A3 Q26786557-4ECF05B7-41C0-4910-B586-44305104EE7B Q27853201-97B4B0C0-65E4-4F8A-9E4A-E9CBADA54BFA Q28074492-AE449792-AA4F-46C2-B02F-EB74A9500D53 Q28084911-25B79D94-2D6D-49AE-B52C-3A8CE4DDD21C Q28085681-4CD05A06-EC43-4B87-A875-A182B6936399 Q30413762-5E7300D2-2078-4B4E-BC61-06E2F2D1B4BA Q33563614-6D119DEA-B45D-4A10-A988-10623DC0D3C4 Q33592489-55C770A7-C0A9-4E1C-B784-838DD676470B Q33610902-29D73985-F0A5-4CFF-9845-1AAF140A0037 Q33674106-4E0CF297-2FA8-4400-A005-91FB6FF548FF Q33709689-6011E812-7D37-4DDE-B779-04B6849EBD0F Q33809465-D8413801-1287-4ED5-859A-184E438F71DB Q33988909-6A1C80E6-A8D1-4E09-BD9C-50774E1CC74A Q34293217-CD6E4A4E-A87D-4C3F-9826-90869BA7293B Q34342517-EFD1E9D7-7C3A-4D9C-AB8C-7385E170B2A9 Q34459061-940D18F0-162C-4C48-BD15-3236D2FF6247 Q34541488-142F4EF7-D666-408D-BCE3-E8422B5DBF6F Q34655450-60845EBA-F613-46C7-90DB-A072C53DD0AE Q35045992-7D015C94-D0EE-4AF6-8A85-11CA340B31AD Q35236465-7C57A5FA-E4F7-47F0-ABA5-957758722210 Q35597530-5AA094AA-1E68-40CC-9AFF-ED7B828ADFD6 Q36080974-1CB55341-1680-49D2-8EDF-77E90B77838E Q36562226-9CCCCE92-1961-4F2F-840A-46FC721E2096 Q36847513-2A235B28-F06F-44C0-8B6C-1D2D6D113E0F Q36881958-F1715CE0-DD8C-460D-8656-0FBE3B98A9C8 Q36989431-CB1F2361-FCBC-4CCC-8C9B-A00D35E23615 Q37065194-8D4D0234-C4F6-4B43-BD01-B99DE79E3802 Q37187733-E98A960E-9D21-49CF-94C4-B8C60F102420 Q37207661-A47B4731-F1D9-43AB-A07F-BE03C6D7D953 Q37218158-B5D36C2F-CE63-4BB3-AD68-57F26C80BFFE Q37268975-866693BB-066D-434A-90A4-B2A570B311ED Q37603268-5B4A5ADF-1AAA-4FDD-B751-D0BEE538B803 Q37745577-87132A36-CFA6-45FA-85C5-C7451B21A2FF Q37999885-54163CDC-92E1-4E11-9853-AAB5789C0658 Q38125641-1170BB05-4A88-4269-8D11-16E1E76C9BF4 Q38185265-87D55DC8-A249-4560-8F2C-3B2CC0562237 Q38186704-448A7FD6-FE77-4C23-A102-AF7F0D46F5D6 Q38218836-33035FD7-E278-4709-B3C1-026F5F5D9B0A Q38283093-D06966DC-1B7B-4264-9DA8-CB4E6F0C2D8E

P2860

EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.

http://www.wikidata.org/entity/Q34803805

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

EZH2-dependent suppression of ...... tion of p21/CDKN1A expression.

@ast

EZH2-dependent suppression of ...... tion of p21/CDKN1A expression.

@en

EZH2-dependent suppression of ...... tion of p21/CDKN1A expression.

@nl

type

label

EZH2-dependent suppression of ...... tion of p21/CDKN1A expression.

@ast

EZH2-dependent suppression of ...... tion of p21/CDKN1A expression.

@en

EZH2-dependent suppression of ...... tion of p21/CDKN1A expression.

@nl

prefLabel

EZH2-dependent suppression of ...... tion of p21/CDKN1A expression.

@ast

EZH2-dependent suppression of ...... tion of p21/CDKN1A expression.

@en

EZH2-dependent suppression of ...... tion of p21/CDKN1A expression.

@nl

P1433

Q34803805-D444AE77-0063-48B3-98DF-26C504A3367C

P1476

Q34803805-6C065CCB-6FE9-48A0-91C1-6662A11DA229

P2093

Q34803805-01AD7032-1463-4025-895F-80C66748633F

Q34803805-15A86D24-4E87-4CC9-B76E-FCC33FFC26CA

Q34803805-479186F8-8E53-4345-BCD7-B5A6778D38ED

Q34803805-C1F73747-2EB6-41DC-847E-0F4DB428DC1D

Q34803805-CC71C940-9887-4754-9668-B9E80ABAB862

Q34803805-D7E3962A-16D8-41A6-B505-ACB4658F677D

Q34803805-EA85E14B-09D7-4F6A-B638-6CF4FE507D18

P2860

Q34803805-025B0B62-793D-489C-B75F-AC5EB0D09D01

Q34803805-042E6A78-6B23-4A71-A19E-8D730CC26AB2

Q34803805-05460216-6D78-41EE-8785-666CE1005F40

Q34803805-06165E70-08E9-471B-823A-85A1DA7C32C6

Q34803805-0A2B03C3-5249-4784-AEE2-B52BE6AD95CA

Q34803805-0BC1F673-DEDC-4E10-9BA1-94D674193965

Q34803805-127343EA-1320-482D-850E-0E313E101409

Q34803805-16136D25-4FAB-496C-9529-A905B58EDB58

Q34803805-1C10BD23-68EF-47F1-B341-A81A621DD389

Q34803805-215DE517-1F22-4400-B175-C0C47A3C47C6

P304

Q34803805-7439BD86-3E1B-4B8C-B02F-A87AA86A9E3F

P31

Q34803805-3F23010F-EF9F-4F58-B662-D82768B3B550

P356

Q34803805-16D4A1B6-2557-4D1A-A60C-370233D8FB91

P433

Q34803805-5153A857-AD75-4FD9-B43F-1CA46F2AF0EE

P478

Q34803805-7CAB8DE9-32F6-4574-8A42-3C9515EC5850

P577

Q34803805-B153345F-3CA2-4523-9450-794CFFB45BF5

P698

Q34803805-F6FE1396-D924-451C-A117-4DE42324F7B7

P932

Q34803805-31E8E5E3-1A70-4E18-BA16-0E968651914A

P356

1541-7786.MCR-10-0511

P1433

Molecular Cancer Research

P1476

EZH2-dependent suppression of ...... tion of p21/CDKN1A expression.

@en

P2093

Ali Alikhan

http://www.w3.org/2001/XMLSchema#string

Christina Ni

http://www.w3.org/2001/XMLSchema#string

Chyi-Chia Richard Lee

http://www.w3.org/2001/XMLSchema#string

Nancy Chung

http://www.w3.org/2001/XMLSchema#string

Shunlin Jiang

http://www.w3.org/2001/XMLSchema#string

Tao Fan

http://www.w3.org/2001/XMLSchema#string

Thomas J Hornyak

http://www.w3.org/2001/XMLSchema#string

P2860

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

A biomarker that identifies senescent human cells in culture and in aging skin in vivo

Genome-wide maps of chromatin state in pluripotent and lineage-committed cells

Combinatorial patterns of histone acetylations and methylations in the human genome

Structural basis for specific binding of Polycomb chromodomain to histone H3 methylated at Lys 27

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs

The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells

Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein

Mutations of the BRAF gene in human cancer

P304

418-429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1541-7786.MCR-10-0511

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21383005

http://www.w3.org/2001/XMLSchema#string

P932

3078218

http://www.w3.org/2001/XMLSchema#string